Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi ...

Novo Nordisk's CEO, who led its boom driven by obesity and diabetes medications only to see that success stall, is stepping ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...

Access to diabetes care in lower-income countries still lags for children, despite efforts from insulin makers.

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic ...